The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations

Gefitinib is an essential drug for NSCLC patients harboring EGFR sensitive mutations. The approved dose 250mg/day is based on limited clinical trials, this research aims to explore the relationship between drug exposure and gefitinib response. C(trough) of 87 NSCLC patients harboring EGFR sensitive...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Sci Rep
Päätekijät: Xin, Shuang, Zhao, Yuanyuan, Wang, Xueding, Huang, Yan, Zhang, Jing, Guo, Ying, Li, Jiali, Li, Hongliang, Ma, Yuxiang, Chen, Lingyan, Hu, Zhihuang, Huang, Min, Zhang, Li
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4521154/
https://ncbi.nlm.nih.gov/pubmed/26228025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep12675
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia